BDTX

Black Diamond Therapeutics' stock has experienced a downtrend of 23.14% in the past six months as of May 26, 2022, but as of May 6, 2026, the share price increased by 81.94% from May 7, 2025. The company reported a net loss of $9.0 million in Q1 2026, compared to a net income of $56.5 million in Q1 2025, which included a $70.0 million upfront license payment from Servier, and ended Q1 2026 with $118.3 million in cash, expected to fund operations into the second half of 2028. Silevertinib Phase 2 data was presented at the 2026 ASCO Annual Meeting. Analysts have a consensus rating of "Strong Buy" with a median price target of $10.77 as of May 8, 2026. Technical signals have been mixed, with some bullish and bearish indicators.